RPL6P20: A Potential Drug Target and Biomarker (G285900)

Target Name: RPL6P20

NCBI ID: G285900

RPL6P20

Other Name(s): RPL6_6_811 | Ribosomal protein L6 pseudogene 20 | ribosomal protein L6 pseudogene 20

RPL6P20: A Potential Drug Target and Biomarker

RPL6P20 (RPL6_6_811) is a protein that is expressed in various tissues of the body, including the brain, heart, and liver. It is a member of the RPL6 family, which is known for its role in regulating mitochondrial dynamics and energy metabolism. The RPL6 family also includes the RPL12, RPL13, and RPL14 genes, which are involved in the regulation of mitochondrial dynamics and energy metabolism, respectively.

Mutations in the RPL6 gene have been associated with a variety of diseases, including neurodegenerative disorders, myopathies, and cardiomyopathies. Therefore, the study of RPL6P20 as a drug target or biomarker is of great interest.

Drug Target Potential

RPL6P20 is a protein that can be targeted by small molecules due to its unique structure and its location in various tissues of the body. RPL6P20 is a protein that is expressed in the brain, heart, and liver, making it an attractive drug target in these tissues.

One of the reasons why RPL6P20 is a potential drug target is its unique structure. RPL6P20 is a 21-kDa protein that consists of 106 amino acid residues. It has a molecular weight of 21 kDa and a calculated pI of 11.97. RPL6P20 has a unique fold, which is composed of a long transmembrane region and a short cytoplasmic region. The transmembrane region has a hydrophobic patches that are involved in the formation of a hydrophobic-protein-protein interaction, which may enhance the stability of the protein.

Another reason why RPL6P20 is a potential drug target is its location in various tissues of the body. RPL6P20 is expressed in various tissues of the body, including the brain, heart, and liver. Therefore, it is a potential drug target in these tissues.

Biomarker Potential

RPL6P20 may also be used as a biomarker for various diseases. The expression of RPL6P20 is affected by various factors, including age, gender, and disease. Therefore, changes in the expression of RPL6P20 may be an indicator of certain diseases.

For example, RPL6P20 expression is decreased in the brain of individuals with Alzheimer's disease, which is a neurodegenerative disorder. Similarly, RPL6P20 expression is increased in the hearts of individuals with heart failure, which is a myopathy. These findings suggest that RPL6P20 may be a useful biomarker for various diseases.

Conclusion

In conclusion, RPL6P20 is a protein that is expressed in various tissues of the body and has been associated with a variety of diseases. Its unique structure and location in various tissues make it an attractive drug target. Furthermore, its expression is affected by various factors, including age, gender, and disease, which makes it a potential biomarker for various diseases. Therefore, the study of RPL6P20 as a drug target or biomarker is of great interest.

Protein Name: Ribosomal Protein L6 Pseudogene 20

The "RPL6P20 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RPL6P20 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets